Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $20.6250.
VIR has been the subject of several recent analyst reports. Leerink Partners raised their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a report on Monday. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday. Morgan Stanley set a $25.00 price target on Vir Biotechnology in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th.
Check Out Our Latest Report on Vir Biotechnology
Vir Biotechnology Stock Up 0.8%
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. The firm had revenue of $238.95 million for the quarter, compared to analyst estimates of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The company’s revenue for the quarter was up 19582.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.80) earnings per share. On average, equities analysts anticipate that Vir Biotechnology will post -2.1 earnings per share for the current year.
Insider Buying and Selling at Vir Biotechnology
In other news, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the sale, the director directly owned 21,216 shares in the company, valued at approximately $200,491.20. This trade represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.90% of the company’s stock.
Institutional Investors Weigh In On Vir Biotechnology
A number of hedge funds have recently added to or reduced their stakes in VIR. BlackRock Inc. acquired a new stake in Vir Biotechnology in the 2nd quarter valued at about $210,712,000. Deutsche Bank AG acquired a new position in shares of Vir Biotechnology during the second quarter worth approximately $1,368,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Vir Biotechnology during the second quarter worth approximately $268,000. SCS Capital Management LLC bought a new stake in shares of Vir Biotechnology during the second quarter valued at approximately $247,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Vir Biotechnology during the second quarter valued at approximately $7,076,000. Institutional investors own 65.32% of the company’s stock.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
See Also
- Five stocks we like better than Vir Biotechnology
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
